Sawai Aims To Overcome US Slide
Japanese Firm Still Optimistic On Meeting Full-Year Forecasts
Executive Summary
Sawai says it is still on track to meet its financial targets for the current financial year, despite a slump in US sales and profits.
You may also be interested in...
Sawai Sets Upsher-Smith $50m+ Target For Former Reddy’s Brands
Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.
Sawai Eyes Global Position Helped By Growth In Japan And Upsher-Smith – But No Biosimilars
In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.